These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 19275707)

  • 1. Drug targets in cytomegalovirus infection.
    Andrei G; De Clercq E; Snoeck R
    Infect Disord Drug Targets; 2009 Apr; 9(2):201-22. PubMed ID: 19275707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of human CMV.
    Andrei G; De Clercq E; Snoeck R
    Curr Opin Investig Drugs; 2008 Feb; 9(2):132-45. PubMed ID: 18246516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus DNA replication: antiviral targets and drugs.
    Mercorelli B; Sinigalia E; Loregian A; Palù G
    Rev Med Virol; 2008; 18(3):177-210. PubMed ID: 18027349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
    Hussein ITM; Brooks J; Bowlin TL
    Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
    Piret J; Boivin G
    Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase.
    Tenney DJ; Yamanaka G; Voss SM; Cianci CW; Tuomari AV; Sheaffer AK; Alam M; Colonno RJ
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2680-5. PubMed ID: 9420038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of letermovir: a cytomegalovirus prophylactic option.
    Gerna G; Lilleri D; Baldanti F
    Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
    O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
    Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
    Neyts J; De Clercq E
    Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.
    Mercorelli B; Lembo D; Palù G; Loregian A
    Pharmacol Ther; 2011 Sep; 131(3):309-29. PubMed ID: 21570424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
    Campos AB; Ribeiro J; Boutolleau D; Sousa H
    Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T; Fuller MD; Mulato AS; Cherrington JM
    Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral treatment of cytomegalovirus infection.
    Ahmed A
    Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein.
    Mercorelli B; Luganini A; Celegato M; Palù G; Gribaudo G; Loregian A
    Antiviral Res; 2018 Feb; 150():130-136. PubMed ID: 29274844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus.
    Posthuma CC; van der Beek MT; van der Blij-de Brouwer CS; van der Heiden PL; Marijt EW; Spaan WJ; Claas EC; Nederstigt C; Vossen AC; Snijder EJ; Kroes AC
    J Clin Virol; 2011 May; 51(1):25-30. PubMed ID: 21388868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro.
    Yamada R; Suda H; Sadanari H; Matsubara K; Tuchida Y; Murayama T
    Antiviral Res; 2016 Jan; 125():79-83. PubMed ID: 26640224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
    Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
    Drouot E; Piret J; Boivin G
    Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.
    Wang Y; Mukhopadhyay R; Roy S; Kapoor A; Su YP; Charman SA; Chen G; Wu J; Wang X; Vennerstrom JL; Arav-Boger R
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
    Bounaadja L; Piret J; Goyette N; Boivin G
    J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.